Regarding vendor selection in support of allogeneic CAR-T therapy specifically, Gregory Opiteck, Ph.D., VP Head of Translational Sciences at Allogene Therapeutics covers top challenges, best practices, and expectations for the short term.
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Please enter your email address and create a password to access the full content, Or
log in to your account to continue.
Please tell us more about you so that we can customize our newsletters to your specific interests: